Bergamot Extract: The Definitive Guide

What is bergamot extract?

Bergamot is Citrus bergamia, a citrus fruit associated with Calabria, Italy. Oral supplements usually use a fruit-derived polyphenol or flavonoid extract containing compounds such as neoeriocitrin, naringin and neohesperidin.

This material differs from bergamot peel essential oil used in fragrance or aromatherapy. A milligram amount is meaningful only when it stays attached to the same extract mass, standardization and marker compounds tested in a source.

Typical Bergamot Extract Protocols

No RDA, AI or UL exists for bergamot extract. These source-specific regimens are not interchangeable with essential oil or an unstandardized citrus blend.

Material

Record oral fruit extract, polyphenol fraction or essential oil; they have different chemistry and evidence.

Standardization

Keep total extract mass and declared flavonoid amount separate, including named marker compounds.

Medication context

Record statins and every other lipid, glucose or blood-pressure treatment.

Laboratory context

Preserve fasting status, laboratory, assay, baseline value and time since the last dose.

What is bergamot extract commonly used for?

Oral extract is marketed for LDL cholesterol, total cholesterol, triglycerides, glucose and “heart health.” The evidence is concentrated in biomarkers and does not establish fewer clinical cardiovascular events.

Claims about statin-like action are largely mechanistic. Structural or laboratory similarities do not give a supplement the outcome evidence, standardized dosing or monitoring of a prescription statin.

Which forms and labels matter?

Look for Citrus bergamia, plant part, extraction method, extract mass per capsule, flavonoids per capsule, named markers, daily serving, furanocoumarin status and independent quality testing. A proprietary product tested in one trial does not validate every product with “bergamot” on the front label.

Essential oil and Earl Grey tea do not reproduce an oral standardized polyphenol-extract protocol. Phototoxicity concerns are most established for furanocoumarin-containing peel oil on skin, but oral product composition still matters.

What does the human evidence show?

Spina randomized 64 adults aged 40–70 with untreated LDL of 160–190 mg/dL and BMI 25–29.9. The active group received one daily capsule containing 375 mg Bergavit extract, standardized to 150 mg flavonoids; placebo substituted maltodextrin. After four months, LDL fell 11.5% and total cholesterol 8.8% in the active group. HDL rose 5.5% but only trended toward significance; oxidized LDL fell 2.0% and PON1 rose 6.5%. Triglyceride and several safety outcomes did not significantly differ. One author was employed by the ingredient supplier. [1]

Lamiquiz-Moneo reviewed 12 eligible human studies from 442 records. Nine of 12 reported lower total cholesterol, triglycerides and LDL, with wide ranges of change; eight reported higher HDL. The review cautioned that preparations and designs were heterogeneous and scientific quality was quite limited. It therefore supports a signal, not one transferable dose or a treatment substitute. [2]

Toth followed 80 adults using 150 mg bergamot flavonoids daily for six months and reported favorable changes from baseline. Its uncontrolled design cannot separate product effects from diet, time, regression to the mean or other changes, and it did not test cardiovascular events. [3]

How might it work?

Bergamot flavonoids may affect cholesterol absorption, lipid synthesis, AMPK signaling, LDL-receptor pathways or oxidative markers. These proposals come from mixed laboratory, animal and biomarker evidence. They do not show that the extract acts exactly like a statin or confers the same event reduction.

What are the risks and interactions?

Reported short-term tolerability does not define uncommon or long-term harms. Gastrointestinal symptoms and allergy are possible. Citrus furanocoumarins can affect drug metabolism, but content varies by extract; the absence of a clear label should not be interpreted as absence.

Review bergamot with statins, calcium-channel blockers, immunosuppressants and other medicines sensitive to grapefruit-like interactions. Additive lipid, glucose or blood-pressure effects can complicate monitoring. Pregnancy, breastfeeding, pediatrics and significant liver or kidney disease remain inadequately studied.

Status in the United States and Canada

In the United States, bergamot extract is sold as a dietary supplement and is not approved to treat dyslipidemia or prevent cardiovascular events.

In Canada, authorized natural health products have product-specific licence conditions. A licence does not establish equivalence to Bergavit or prove statin replacement.

What should be monitored?

Record product, lot, extract mass, standardized flavonoids, administration time, medications, symptoms and clinician-directed lipid or safety labs. Keep baseline and follow-up conditions comparable, and record medication or diet changes alongside results.

What happens after stopping?

No withdrawal syndrome or taper is established. Lipid markers may return toward the untreated trajectory; medication decisions and repeat testing should be clinician-directed.

How should it be stored?

Follow the finished-product label, protect capsules from heat and moisture, retain the lot and expiry date and store out of children’s reach. Essential oils need separate handling and should never be substituted dose-for-dose.

Community experiences

Anecdotes often omit baseline LDL, concurrent statin use, diet changes and the standardized extract. A single before-and-after laboratory result cannot isolate causation.

How does it compare with other approaches?

Statins and other approved lipid-lowering medicines have standardized dosing and cardiovascular-outcome evidence for defined risk groups. Diet, exercise and smoking cessation address broader risk. Bergamot’s biomarker signal does not make it equivalent to these approaches.

Frequently asked questions

What exact protocol did Spina use?

One capsule daily containing 375 mg Bergavit extract standardized to 150 mg flavonoids for four months. [1]

Was the 2024 trial authored by Nobile?

The correct citation is Spina et al.; Vincenzo Nobile is the last author. [1]

Is bergamot essential oil the studied lipid product?

No. The cited lipid studies used oral fruit extracts or polyphenol fractions, not fragrance oil.

Can bergamot replace a statin?

No cited trial establishes equivalent cardiovascular-event prevention. Medication changes require clinical direction.

Does a lower LDL prove fewer heart attacks?

No. LDL is an important biomarker, but these bergamot studies did not measure event reduction.

Should liver tests be monitored?

A clinician may choose baseline or follow-up tests based on medicines, disease and product. The short trial safety panel does not settle long-term risk.

Glossary

Terms used in this guide.

Bergamot

The citrus species Citrus bergamia.

Flavonoid

Plant compound class used to standardize some bergamot extracts.

LDL cholesterol

Lipoprotein-associated cholesterol biomarker used in cardiovascular-risk assessment.

Oxidized LDL

Modified LDL biomarker measured in some mechanistic studies.

Paraoxonase 1 (PON1)

Enzyme activity biomarker measured in the Spina trial.

Furanocoumarin

Citrus compound class that can contribute to phototoxicity or drug-metabolism interactions depending on exposure.

How this guide was researched

This draft prioritizes the current standardized randomized trial, then uses the human systematic review and a longer uncontrolled study to define consistency and limits. Evidence checked October 9, 2026.

How this guide was made

The research ledger preserves extract mass, flavonoid standardization, per-administration frequency, duration, design, endpoints, conflicts and access limits.

Sources

Related guides